Evaluating the Efficiency of Long Term Oxygen Therapy and Mortality in Chronic Obstructive Pulmonary Disease

医学 氧气疗法 慢性阻塞性肺病 低氧血症 红细胞压积 内科学 死亡率 肺动脉高压 药方 肺病 动脉血 心脏病学 药理学
作者
Nurcan Türkoğlu,Tacettin Örnek,Figen Atalay,Fatma Erboy,Bülent Altınsoy,Hakan Tanrıverdi,Fırat Uygur,Figen Atalay
出处
期刊:Electronic journal of general medicine [Modestum Limited]
卷期号:12 (1) 被引量:2
标识
DOI:10.15197/sabad.1.12.04
摘要

It has been shown that Long Term Oxygen Therapy (LTOT) improves polycythemia secondary to hypoxemia and right heart failure, decreases pulmonary hypertension, improves quality of life and increases life expectancy in COPD patients. In our study we aimed to evaluate clinical data, mortality, patient's adherence and efficiency of the therapy in COPD patients receiving LTOT. Mean age was 70.5%±9.7 and 57% of the participiants were male. It was shown that one year hospital admission count after LTOT (0.56±0.79) was decreased according to one year hospital admission count before LTOT (1.14±1.64). When arterial blood gas values after LTOT compared to the values at the time prescription PaO2 was increased (47.9±4, 53.4±9) and PaCO2 was decreased (56.1±11, 50.5±11). Although there was no significant difference in pulmonary artery pressure after LTOT, a significant increase was determined in hematocrit (38.37±6, 40.14±6). 41.1% of the patients had at least once device maintanence, and after LTOT only 38.4% had a clinical control due to COPD. The most common reason for irregular use was lack of necessity. Mean daily oxygen usage was 13.88±4.35 hours/day and 68.8% of the patients were using 15 hours or more. Mean follow-up of the patients were 17.85±14.53 (1-55) months and mortality rate in this period was 67%. Mortality was higher in LTOT with 15hours/day or more compared to less than 15 hours (respectively 54.6%, 12.5%). In conclusion, all patients with an indication for LTOT should be followed by national registry system and monitored in terms of technical services. Patients adherence and routine controls should be provided.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lssah完成签到,获得积分10
1秒前
寒冷的凝旋完成签到,获得积分10
1秒前
善学以致用应助WSDD-ya采纳,获得30
2秒前
David完成签到,获得积分10
2秒前
猛犸象冲冲冲完成签到,获得积分10
3秒前
yk完成签到 ,获得积分10
3秒前
cdercder应助傻大采纳,获得10
3秒前
mia发布了新的文献求助10
4秒前
5秒前
Myx完成签到,获得积分10
5秒前
5秒前
wanci应助BenLuo采纳,获得10
5秒前
zimo发布了新的文献求助10
5秒前
6秒前
科研通AI5应助科研通管家采纳,获得10
6秒前
6秒前
研友_VZG7GZ应助科研通管家采纳,获得10
6秒前
yy应助科研通管家采纳,获得10
6秒前
小李老博应助科研通管家采纳,获得10
6秒前
小蘑菇应助于浩采纳,获得10
6秒前
8R60d8应助科研通管家采纳,获得10
6秒前
8R60d8应助科研通管家采纳,获得10
6秒前
共享精神应助科研通管家采纳,获得10
6秒前
小二郎应助科研通管家采纳,获得10
6秒前
7秒前
7秒前
婷婷完成签到,获得积分10
7秒前
九儿完成签到 ,获得积分10
8秒前
8秒前
111完成签到 ,获得积分10
8秒前
WELXCNK完成签到,获得积分10
9秒前
殷勤的紫槐完成签到,获得积分10
9秒前
含蓄大雁发布了新的文献求助10
10秒前
新新新新新发顶刊完成签到,获得积分10
10秒前
所所应助20240901采纳,获得10
10秒前
所所应助zimo采纳,获得10
10秒前
小破网完成签到 ,获得积分0
11秒前
LiDaYang完成签到,获得积分10
11秒前
WX发布了新的文献求助10
11秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
All the Birds of the World 4000
Production Logging: Theoretical and Interpretive Elements 3000
Musculoskeletal Pain - Market Insight, Epidemiology And Market Forecast - 2034 2000
Animal Physiology 2000
Am Rande der Geschichte : mein Leben in China / Ruth Weiss 1500
CENTRAL BOOKS: A BRIEF HISTORY 1939 TO 1999 by Dave Cope 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3746640
求助须知:如何正确求助?哪些是违规求助? 3289434
关于积分的说明 10064680
捐赠科研通 3005779
什么是DOI,文献DOI怎么找? 1650416
邀请新用户注册赠送积分活动 785876
科研通“疑难数据库(出版商)”最低求助积分说明 751335